Pharma companies directory 2026

    Pharmaceutical Companies in Peru

    Peru’s laboratory channel is smaller and more import-dependent than its Andean neighbours: IQVIA figures cited by Gestión put 2024 laboratory sales at S/ 4.49 billion, down 1 percent in value and 6 percent in units, after DIGEMID declined to renew a wave of category-3 sanitary registrations.

    DIGEMID, inside the Ministry of Health, is the registration and inspection authority. Demand then splits along an insurance line that is unusually sharp even by Latin American standards: SIS, the subsidised public scheme run with MINSA, reaches about 60 percent of Peruvians, EsSalud covers formal-sector workers at roughly 30 percent, and the remainder sit with the armed forces, police or private plans. Domestic plants — Farmindustria, Medifarma, Laboratorios Portugal, AC Farma, Hersil — win a large share of SIS and EsSalud generic lots, while innovator affiliates (Pfizer, Abbott, Roche, Novartis) import most of the specialty book and sell it into private clinics and selected EsSalud high-cost programmes. Generic-promotion rules that push INN prescribing have flattened some branded-generic premiums in the public channel without erasing brand loyalty at Inkafarma and Mifarma, the InRetail pair that now frames private pharmacy traffic in Lima. Roemmers Perú and Tecnofarma show how Argentine and regional groups treat Lima as a second home market rather than a satellite. The list below is the set BioNixus uses when a client asks who can actually put a molecule on a MINSA shelf, an EsSalud formulary or a chain planogram in Lima, Arequipa or Trujillo.

    Updated September 2026 · DIGEMID — registros sanitarios de medicamentos and licensed establishments as of September 2026 · 19 named accounts

    Request a proposal for PeruBrowse the 19 companies

    S/ 4.49bn

    Laboratory sales in 2024, IQVIA/IMS as reported by Gestión

    −1.0%

    Year-on-year change in laboratory billing, 2024 (IQVIA/IMS via Gestión)

    −6.1%

    Year-on-year change in units sold, 2024 (IQVIA/IMS via Gestión)

    ~60%

    Population covered by MINSA / SIS (U.S. Commercial Service)

    Named accounts

    Top pharmaceutical companies in Peru

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against DIGEMID — registros sanitarios de medicamentos and licensed establishments (as of 2026-09-04).
    #CompanyHQ
    01DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)Lima
    02EsSaludLima
    03SIS (Seguro Integral de Salud)Lima
    04Ministerio de Salud (MINSA)Lima
    05FarmindustriaLima
    06MedifarmaLima
    07Laboratorios PortugalLima
    08Roemmers PerúLima
    09TecnofarmaLima
    10Laboratorios AC FarmaLima
    11Laboratorios HersilLima
    12Laboratorios UniónLima
    13Abbott PerúLima
    14Pfizer del PerúLima
    15Roche PerúLima
    16Novartis PerúLima
    17Química Suiza (Quicorp)Lima
    18InkafarmaLima
    19MifarmaLima

    Primary research

    These are the pharmaceutical companies accounts we study in Peru

    Need account-level or SKU-level data for a brand in Peru? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

    Planning research in Peru?

    Primary research, market access & HEOR. Proposals within 48 hours.

    Top healthcare market research companies in Peru (2026)

    How the market is structured

    How DIGEMID, SIS, EsSalud and the InRetail chains divide Peru

    DIGEMID issues the registro sanitario, inspects plants and has used non-renewal of category-3 products as a quality filter; Gestión’s 2024–2025 coverage, quoting local general managers, tied the unit contraction directly to those lost files. A foreign originator without a Lima affiliate appoints a Peruvian holder — often Química Suiza, Tecnofarma or a domestic lab — to own the registration and to clear Callao. Public purchasing is not a single national tender. MINSA and SIS facilities buy for the subsidised majority, EsSalud runs its own formulary and hospital network for contributing workers, and the two sometimes join the armed forces in consolidated lots that still leave room for separate institutional awards. Generic-promotion law and INN-prescribing rules are meant to steer those lots toward the cheapest registered pack, which is why Farmindustria, Medifarma and Portugal compete on price and on DIGEMID-clean dossiers rather than on brand story inside MINSA. Private demand is a different sport. Inkafarma and Mifarma, both under InRetail Pharma, concentrate Lima and coastal-city pharmacy traffic; their category desks decide OTC and chronic-repeat visibility, while independent boticas still matter in Arequipa, Trujillo and the sierra. Innovator affiliates detail private-clinic specialists and EsSalud high-cost committees, then import finished packs rather than formulating locally. Distribución sits with Química Suiza and a handful of other mayoristas that carry both domestic generics and imported specialties on credit. A Peru plan that treats SIS, EsSalud and InRetail as one channel will mis-forecast both price and mix.

    Local

    Lima manufacturers — Farmindustria, Medifarma, Portugal, AC Farma, Hersil, Unión — that price DIGEMID-clean generics into SIS and EsSalud lots and still hold some pharmacy brands.

    • Farmindustria
    • Medifarma
    • Laboratorios Portugal
    • Laboratorios AC Farma
    • Laboratorios Hersil
    • Laboratorios Unión

    Multinational

    Innovator affiliates that import specialty and nutrition packs, selling into EsSalud high-cost programmes and private clinics rather than into SIS price contests.

    • Abbott Perú
    • Pfizer del Perú
    • Roche Perú
    • Novartis Perú

    Regional

    Roemmers Perú and Tecnofarma, Andean groups that treat Lima as a home detailing market and sometimes hold files for originators without an affiliate.

    • Roemmers Perú
    • Tecnofarma

    Distributors & importers

    Química Suiza, Inkafarma, Mifarma and the public triad of DIGEMID, SIS and EsSalud that decide whether a registered pack is a tender SKU or a chain SKU.

    • DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)
    • EsSalud
    • SIS (Seguro Integral de Salud)
    • Ministerio de Salud (MINSA)
    • Química Suiza (Quicorp)
    • Inkafarma
    • Mifarma

    What is moving

    What is moving the pharmaceutical market in Peru

    DIGEMID category-3 clean-up

    Non-renewal of a large set of sanitary files in 2023–2024 cut laboratory portfolios and units; companies with remaining clean dossiers inherited share without launching anything new.

    Generic-promotion and INN prescribing

    Rules that push international non-proprietary names in the public channel keep SIS and many EsSalud lots as price contests, rewarding Farmindustria, Medifarma and Portugal.

    SIS versus EsSalud split

    Two public payers with different formularies, payment clocks and clinical cultures mean a single “Peru public” forecast will mis-state both price and mix.

    InRetail pharmacy concentration

    Inkafarma and Mifarma now frame private traffic in Lima and coastal cities, so OTC and chronic-repeat brands live or die on two category desks rather than on a long botica route.

    Imported innovator specialties

    Pfizer, Roche, Novartis and Abbott still bring most high-value packs through Callao, which keeps private-clinic and EsSalud high-cost access as the growth lane that domestic plants do not occupy.

    BioNixus fieldwork

    How BioNixus studies pharmaceutical companies in Peru

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Peru:
    • SIS versus EsSalud purchasing interviews in Lima, splitting generic lot prices from high-cost committee behaviour on the same therapy class.
    • DIGEMID category-3 loss mapping: which laboratory portfolios shrank in 2023–2024 and which remaining files inherited unit share.
    • InRetail category interviews covering Inkafarma and Mifarma listings, private label and chronic-repeat planograms.
    • Pharmacy and hospital audits in Lima, Arequipa and Trujillo estimating domestic-generic versus imported-innovator mix by channel.

    Questions

    Frequently Asked Questions

    Which pharmaceutical companies manufacture in Peru?

    Farmindustria, Medifarma, Laboratorios Portugal, AC Farma, Hersil and Unión are the domestic names that recur in DIGEMID plant lists and in SIS / EsSalud lots. Roemmers Perú and Tecnofarma add regional branded-generic capacity. Innovator affiliates import most of what they sell.

    How long does DIGEMID registration take, and what is category 3?

    Timelines depend on dossier type and on whether the plant is already known to DIGEMID. Category-3 products faced a wave of non-renewals in 2023–2024 that Gestión and local managers linked to the 2024 unit drop. A file that cannot be renewed is a lost SKU, not a delayed one.

    How do SIS and EsSalud differ for manufacturers?

    SIS, with MINSA facilities, covers about three in five Peruvians and buys mostly low-priced generics. EsSalud covers contributing workers, runs its own hospitals and is the public door for more specialty and high-cost lines. Joint lots happen, but formularies and payment clocks are not the same.

    Do generic-promotion rules erase pharmacy brands?

    They flatten premiums inside MINSA and many EsSalud lots, where INN prescribing is enforced. They do not erase brand choice at Inkafarma and Mifarma, where shoppers and chain private labels still decide the till. Companies therefore keep two stories for the same molecule.

    What fieldwork does BioNixus use to profile Peruvian pharmaceutical companies?

    DIGEMID dossier and category-3 loss reviews; SIS and EsSalud purchasing interviews; InRetail category discussions; and pharmacy plus hospital work in Lima, Arequipa and Trujillo to split public lots from chain sell-out.

    Does this Peru page rank laboratories by market share?

    No. Entries were chosen because they recur in DIGEMID registers, EsSalud and SIS purchasing, and BioNixus Lima fieldwork. Placement on the page is not a share estimate.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Peru. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: DIGEMID — registros sanitarios de medicamentos and licensed establishments, consulted 2026-09-04. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Peru, not size.

    • Gestión, Análisis del mercado farmacéutico en Perú, citing IQVIA/IMS 2024 laboratory sales (S/ 4,487 million; −1.01% value; −6.07% units)
    • U.S. Commercial Service, Peru healthcare-system coverage (MINSA/SIS ~60%; EsSalud ~30%)
    • DIGEMID / MINSA registration and generic-promotion rules; InRetail Pharma public materials on Inkafarma and Mifarma
    • BioNixus Peru public-purchasing, chain and hospital fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need brand and competitor data in Peru?

    Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

    Planning research in Peru?

    Primary research, market access & HEOR. Proposals within 48 hours.